Borealis Biosciences develops RNA therapeutics specifically targeting kidney diseases, utilizing advanced methods for targeted delivery to renal cells. The company addresses the lack of effective treatments for prevalent chronic kidney conditions, aiming to improve patient outcomes and reduce the incidence of kidney failure.
Funding
$30M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
WVFounders
Product
Problem
Chronic kidney diseases affect a significant portion of the global population, and many prevalent forms lack effective treatments. This can lead to kidney failure, requiring dialysis or transplantation, and significantly impacting patients' lives. Validated causal targets for these diseases have not been amenable to traditional small molecule or biologic modalities.
Solution
Borealis Biosciences is developing RNA therapeutics specifically designed to address kidney diseases with high unmet need. The company focuses on directing RNA to kidney cells, leveraging scientific and translational breakthroughs in RNA medicines. Borealis' approach aims to improve patient outcomes and reduce the incidence of kidney failure by targeting previously inaccessible disease mechanisms. Their experienced team utilizes expertise in kidney disease, targeted delivery of RNA therapeutics, and translational systems biology to develop these novel treatments.
Target Audience
The primary target audience includes patients suffering from chronic kidney diseases and the healthcare providers who treat them.
Features
- Targeted delivery of RNA therapeutics to kidney cells
- Focus on kidney diseases with large unmet needs
- Utilizes translational systems biology and data sciences
- Development of RNA medicines to treat kidney diseases